Just 9.5% of Life Sciences M&A Milestones Have Been Paid Since 2008

A new analysis from SRS Acquiom puts into perspective the headline values seen when a company announces a backloaded M&A deal. Biotechs have much on the line when they agree to deals with massive potential but little upfront.